Focused On-demand Library for DNA-directed RNA polymerase III subunit RPC1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
O14802

UPID:
RPC1_HUMAN

ALTERNATIVE NAMES:
DNA-directed RNA polymerase III largest subunit; DNA-directed RNA polymerase III subunit A; RNA polymerase III 155 kDa subunit; RNA polymerase III subunit C160

ALTERNATIVE UPACC:
O14802; Q8IW34; Q8TCW5

BACKGROUND:
The DNA-directed RNA polymerase III subunit RPC1, a key component of RNA polymerase III, catalyzes the transcription of DNA into RNA, crucial for the synthesis of small RNAs such as 5S rRNA and tRNAs. It plays a significant role in the cellular response to infection by acting as a nuclear and cytosolic DNA sensor involved in the innate immune response, detecting non-self dsDNA and initiating the RIG-I pathway.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in genetic transcription and the innate immune response, DNA-directed RNA polymerase III subunit RPC1 presents a promising target for drug discovery. Its association with diseases like Leukodystrophy, hypomyelinating, 7, and Wiedemann-Rautenstrauch syndrome highlights the therapeutic potential of targeting this protein in disease management and treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.